Region — International. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  SNAP-8 (Acetyl Octapeptide-3)
Research reference — not for sale

SNAP-8 (Acetyl Octapeptide-3)

C
lead outcome
Topical: appearance of expression lines
grades vary by outcome ↓
Peptide
also called — SNAP-8 · INCI: Acetyl Octapeptide-3 · an elongated version of Argireline (Acetyl Hexapeptide-8)
skin appearance (cosmetic)expression lines / dynamic wrinkles

Cosmetic — the "next-generation Argireline," with thinner evidence than its parent. Same SNARE/SNAP-25 mechanism and the same "botox" claim minefield as Argireline (#27), but marketed as more potent. The honest twist: its headline numbers are manufacturer-only, and Argireline actually has the larger, more independent evidence base.

In brief

SNAP-8 (Acetyl Octapeptide-3) is an elongated version of Argireline that works through the same SNARE / SNAP-25 mechanism and is marketed as a more potent "topical botox." Its headline figures — "up to ~63% wrinkle-depth reduction," "~30% more active than Argireline" — come from manufacturer studies; there is essentially no independent standalone RCT, and, notably, Argireline itself has the larger and more independent evidence base. Reaching the neuromuscular junction through intact skin is doubtful. It is a cosmetic ingredient only — not botulinum toxin.

Legal standing, by region
European Union
Lawful cosmetic

a lawful cosmetic ingredient (EU Regulation (EC) 1223/2009; US cosmetic law), sold over-the-counter worldwide. No injectable/research lane. Sellable as a cosmetic — the constraint is the claims.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Topical: appearance of expression lines
Manufacturer-dominated; no independent standalone RCT; the ~63% figure is not independently replicated
Manufacturer in-vivo (Lipotec, n=17, 10%, 28 days, "~63%") + in-vitro SNARE assays · Manufacturer-reported improvement
C
"~30% more active than Argireline"
A manufacturer claim; Argireline has the larger independent evidence base — "newer/more potent" ≠ better-evidenced
Manufacturer in-vitro/in-vivo comparison · Claimed
D
Reaching the neuromuscular junction at cosmetic doses
Same stratum-corneum barrier as Argireline
Penetration considerations · Doubtful
D
"Works like Botox"
No trial vs botulinum toxin; mechanism is different (reversible competition) and much weaker
None (no head-to-head) · Not demonstrated
F
"Up to 63% reduction in wrinkle depth" headline magnitude
Wrinkle depth was measured, but only in a single manufacturer-run periocular study of 17 subjects at 10% peptide over 28 days; no independent group has reproduced the figure, and the concentration tested is far above what finished cosmetics contain
Marketing claim
D
Safety (topical)
Regarded as safe as used
Broad cosmetic use · Well tolerated
—
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for SNAP-8 (Acetyl Octapeptide-3) changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

Cosmetic claims boundary
✓ Allowed (appearance / feel)
  • helps reduce the **appearance** of expression lines
  • for smoother-looking skin around the eyes and forehead.
✕ Not allowed (medicinal)
  • topical botox
  • botox alternative
  • relaxes muscles
  • reduces acetylcholine / neurotransmitter release

The medicinal-sounding science stays in the reference section; product copy speaks only to appearance/feel (Reg 655/2013). Different fields, never merged.

Identity

a synthetic octapeptide (8 amino acids, < 40 aa → peptide) patterned on the N-terminal end of SNAP-25, with two extra amino acids added to Argireline's hexapeptide to extend coverage of the SNAP-25 target region.

Development & history

  • Developed by the Spanish biotech Lipotec (Barcelona; now Lubrizol Life Science) — the same company that made Argireline — as its "next-generation" extension. Adding alanine + aspartate to Argireline's sequence was intended to improve binding to the SNARE complex, and Lipotec reported it ~30% more active than Argireline in the company's own in-vitro/in-vivo testing.
  • Genericised and now widely used, often paired with Argireline, Leuphasyl or Matrixyl in serums. Like Argireline, it has only ever been a cosmetic ingredient, never a drug.

Mechanism (as proposed)

like Argireline, SNAP-8 mimics the N-terminal of SNAP-25 and is proposed to compete for SNARE-complex assembly, reducing Ca²⁺-dependent acetylcholine release at the neuromuscular junction and thus facial-muscle contraction. This differs fundamentally from botulinum toxin (which enzymatically cleaves SNAP-25). The evidence is largely in vitro / manufacturer-derived, and whether enough peptide crosses intact skin at cosmetic concentrations to act on the NMJ is doubtful.

Related reading

How the neurotransmitter ("topical Botox") peptides like SNAP-8 fit into a routine — and why this class is the most oversold — in how to use peptides. For where SNAP-8 ranks among the cosmetic peptides by evidence, see cosmetic peptides ranked by evidence — and the head-to-head with its parent peptide in SNAP-8 vs Argireline.

Scan your productSee if SNAP-8 (Acetyl Octapeptide-3) is in what you're usingOpen the scanner →
Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

PubChem CID71587832
InChIKeyQGGBBQJHVCVVKM-XOBYPWAZSA-N
SMILESC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=C)[C@H](CCC(=O)O)NC(=O)C

via PubChem exact-name match (SNAP-8) · high confidence

Sources — 3 cited
01Lipotec / Lubrizol manufacturer documentation — in-vitro SNARE-competition assay and in-vivo periocular study (n=17, 10%, 28 days).
02(No independent standalone RCT of SNAP-8 has been published — cite one only if it appears.)
03Blanes-Mira C, et al. (2002) — the foundational Argireline SNARE-inhibition work the class rests on.
Updated 2026-07-20

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
Argireline (Acetyl Hexapeptide-8)C
Peptide
Matrixyl (Palmitoyl Pentapeptide-4)B
Peptide
GHK-Cu Peptide (Copper Tripeptide-1)B
Peptide
Explore by goal
Skin & aesthetic →
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen dataBrands
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.